Agios Pharmaceuticals (NASDAQ:AGIO) Stock: Insider Sarah Gheuens Sells 1,489 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 1,489 shares of the business’s stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $37.53, for a total value of $55,882.17. Following the completion of the sale, the insider owned 54,645 shares in the company, valued at $2,050,826.85. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Gheuens also recently made the following trade(s):

• On Thursday, October 22nd, Sarah Gheuens sold 500 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $37.52, for a total value of $18,760.00.
• On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $30.48, for a total value of $914,400.00.

Agios Pharmaceuticals Trading Down 0.5%

Shares of NASDAQ:AGIO opened at $37.00 on Friday. The company has a 50 day moving average of $33.41 and a 200 day moving average of $32.79. The stock has a market cap of $2.21 billion, a P/E ratio of -5.28 and a beta of 0.63. Agios Pharmaceuticals, Inc. has a 12 month low of $22.24 and a 12 month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. The firm had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. On average, equities analysts forecast that Agios Pharmaceuticals, Inc. will post -5.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AGIO has been the topic of a number of research reports. TD Cowen raised Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, September 21st. JPMorgan Chase & Co. increased their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. HC Wainwright increased their price objective on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, Bank of America raised their target price on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $41.50.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors have recently bought and sold shares of AGIO. BlackRock Inc. purchased a new stake in Agios Pharmaceuticals during the 2nd quarter valued at $239,582,000. Assenagon Asset Management S.A. increased its position in shares of Agios Pharmaceuticals by 1,714.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock valued at $62,723,000 after purchasing an additional 1,782,457 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in Agios Pharmaceuticals during the second quarter valued at approximately $47,800,000. Dimensional Fund Advisors LP increased its stake in shares of Agios Pharmaceuticals by 14.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,151,614 shares of the biopharmaceutical company’s stock worth $38,940,000 after purchasing an additional 147,273 shares in the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth $24,828,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.